Myriad Genetics Balance Sheet Health
Financial Health criteria checks 4/6
Myriad Genetics has a total shareholder equity of $731.7M and total debt of $39.0M, which brings its debt-to-equity ratio to 5.3%. Its total assets and total liabilities are $1.1B and $349.6M respectively.
Key information
5.3%
Debt to equity ratio
US$39.00m
Debt
| Interest coverage ratio | n/a |
| Cash | US$99.90m |
| Equity | US$731.70m |
| Total liabilities | US$349.60m |
| Total assets | US$1.08b |
Recent financial health updates
Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?
Nov 02
Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?
Jul 17Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
Mar 28Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?
Aug 07Recent updates
Myriad Genetics: Navigating Through A Setback
Jan 16An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued
Jan 08Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 13Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?
Nov 02Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge
Nov 02Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?
Sep 20Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking
Aug 30Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?
Jul 17Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?
Jun 05Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
May 11Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report
May 09Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
Mar 28An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued
Feb 02Myriad Genetics' Strategic Growth Fuels Bullish Outlook
Jan 31Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price
Dec 18Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?
Aug 07Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Apr 13Financial Position Analysis
Short Term Liabilities: MYGN's short term assets ($293.2M) exceed its short term liabilities ($154.3M).
Long Term Liabilities: MYGN's short term assets ($293.2M) exceed its long term liabilities ($195.3M).
Debt to Equity History and Analysis
Debt Level: MYGN has more cash than its total debt.
Reducing Debt: MYGN's debt to equity ratio has reduced from 20.9% to 5.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MYGN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MYGN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 22:21 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Myriad Genetics, Inc. is covered by 43 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Meehan | Barclays |
| Derek Taller | Benchmark Company |
| Michael Ryskin | BofA Global Research |